Anzeige
Erschienen in:
20.06.2017 | Original Scientific Report
Superselective Transarterial Chemoembolization as an Alternative to Surgery in Symptomatic/Enlarging Liver Hemangiomas
Erschienen in: World Journal of Surgery | Ausgabe 11/2017
Einloggen, um Zugang zu erhaltenAbstract
Background
Transarterial embolization of liver hemangiomas has not been considered to be consistently effective.
Methods
The charts of 25 patients who underwent superselective transarterial chemoembolization with the bleomycin–lipiodol emulsion were evaluated retrospectively.
Results
Twenty-two patients had abdominal pain; asymptomatic/vaguely symptomatic enlargement was the treatment indication in three patients. A single session was conducted in 17 patients, two sessions in 7 and three sessions in one. After the first session, lesion volume decreased by median (range) 51% (10–92%) from median (range) 634 (226–8435) to 372(28–4710) cm3 (p < 0.01), after a median period of 4 months (range 2–8). A second session was performed in eight patients (median (range) initial volume 1276 (441–8435) cm3) with persistent complaints and/or large lesions receiving feeders from both right and left hepatic arteries (staged treatment). Median (range) lesion size decreased further from 806 (245–4710) to 464 (159–2150) cm3 (p < 0.01). Three patients experienced a postembolization syndrome that persisted after the first week. Seventeen of the 22 symptomatic patients (77%) reported resolution or marked amelioration of complaints. Regrowth after initial regression was not observed during median (range) 14 (8–39) months of follow-up (n:18).
Conclusion
Transarterial chemoembolization with the bleomycin–lipiodol emulsion is a potential alternative to surgery for symptomatic/enlarging liver hemangiomas. Volume reduction is universal, and symptom control is satisfactory. Centrally located and very large (>1000 cm3) lesions may require two sessions.